127978-70-5

Basic information

• Product Name: (5-METHOXYPYRIDIN-2-YL)METHANOL
• Synonyms: (5-METHOXYPYRIDIN-2-YL)METHANOL;2-Pyridinemethanol,5-methoxy-(9CI);(5-Methoxypyridine-2-yl)methanol;(5-Methoxy-2-pyridyl)methanol;2-(Hydroxymethyl)-5-methoxypyridine;5-Methoxy-2-PyridineMethanol;(5-methoxypyridin-2-yl)methanol hydrochloride;3-Methoxy-6-pyridinemethanol
• CAS NO: 127978-70-5
• Molecular Formula: C₇H₉NO₂
• Molecular Weight: 139.15
• Product Categories: PYRIDINE
• Mol File: 127978-70-5.mol

Chemical Properties

• Boiling Point: 262℃
• Flash Point: 112℃
• Appearance: /
• Density: 1.155
• Refractive Index: 1.534
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 13.22±0.10(Predicted)
• CAS DataBase Reference: (5-METHOXYPYRIDIN-2-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (5-METHOXYPYRIDIN-2-YL)METHANOL(127978-70-5)
• EPA Substance Registry System: (5-METHOXYPYRIDIN-2-YL)METHANOL(127978-70-5)

Safety Data

• Hazardous Substances Data: 127978-70-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(5-METHOXYPYRIDIN-2-YL)METHANOL is used as a key intermediate in the synthesis of substituted pyrrolopyridinones. These compounds act as HPK1 antagonists, which have potential applications in the treatment of various diseases, such as autoimmune disorders and cancer. The development of HPK1 antagonists using (5-METHOXYPYRIDIN-2-YL)METHANOL as a starting material can lead to the creation of novel therapeutic options for patients suffering from these conditions.

InChI:InChI=1/C7H9NO2/c1-10-7-3-2-6(5-9)8-4-7/h2-4,9H,5H2,1H3

Upstream product

• 75342-32-4 2-acetoxymethyl-5-methoxypyridine 
• 35392-66-6 5-methoxy-2-methylpyridine-1-oxide 
• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 55270-47-8 5-methoxy-2-picoline 
• 22187-96-8 5-methoxy-2-pyridinecarboxaldehyde 
• 29681-39-8 5-methoxypyridine-2-carboxylic acid methyl ester 

Downstream Products

• 75342-33-5 2-chloromethyl-5-methoxy-pyridine 
• 22187-96-8 5-methoxy-2-pyridinecarboxaldehyde 
• 357613-18-4 (S)-(+)-N-[(1E)-(5-methoxy-2-pyridinyl)methylidene]-4-methylbenzenesulfinamide 
• 1126369-07-0 N-(5-(1H-imidazol-2-yl)-2-methylphenyl)-4-((5-methoxypyridin-2-yl)methoxy)benzamide 
• 1301167-92-9 5-methoxy-2-[4-[4-(4-pyridinyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]phenoxymethyl]pyridine 
• 1301167-90-7 2-[4-[1-(2-fluoroethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxymethyl]-5-methoxypyridine 
• 1301168-07-9 2-[4-[1-(3-fluoropropyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxymethyl]-5-methoxypyridine 
• 1301167-79-2 {5-[4-(5-methoxypyridin-2-ylmethoxy)-phenyl]-4-pyridin-4-yl-pyrazol-1-yl}-acetic acid methyl ester 
• 1301167-78-1 C₂₄H₂₂N₄O₄ 
• 1301167-80-5 2-[3-[4-(5-methoxy-pyridin-2-yl)methoxyphenyl]-4-(pyridin-4-yl)pyrazol-1-yl]ethanol 
• 1301167-91-8 2-[4-[1-(2-⁽¹⁸⁾F-fluoroethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxymethyl]-5-methoxypyridine 
• 1301167-81-6 C₂₄H₂₄N₄O₅S 
• 1301168-20-6 5-cyclopropyl-2-[4-[1-(2-fluoroethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxymethyl]pyridine 
• 1301168-09-1 5-(2-fluoroethoxy)-2-[[4-[1-(3-fluoropropyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-pyridine 

Relevant articles and documents

Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2

N-Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) that play critical roles in inflammatory reactions, and FPR-specific interactions can possibly be used to facilitate the resolution of pathological inflammatory reactions. We here report the synthesis and biological evaluation of six pairs of chiral ureidopropanamido derivatives as potent and selective formyl peptide receptor-2 (FPR2) agonists that were designed starting from our lead agonist (S)-3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]-N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]propanamide ((S)-9a). The new compounds were obtained in overall yields considerably higher than (S)-9a. Several of the new compounds showed agonist properties comparable to that of (S)-9a along with higher selectivity over FPR1. Molecular modeling was used to define chiral recognition by FPR2. In vitro metabolic stability of selected compounds was also assessed to obtain preliminary insight on drug-like properties of this class of compounds.

Practical and efficient synthesis of N-fused tricyclic indoles

A practical and efficient synthesis of methyl 6,7,8,9-tetrahydropyrido[1,2- a]indol-10-ylacetate derivatives 6 is reported. This synthetic approach featured the nucleophilic aromatic substitution of 2-piperidinemethanol derivatives 2 with aryl fluorides 1

HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS

The present disclosure relates to heterocyclic amide compounds, which are useful for inhibiting the Hedgehog pathway, and their use in treating a disease or medical condition mediated alone or in part by Hedgehog pathway inhibition. Also disclosed are methods for manufacture of these compounds, pharmaceutical compositions including these compounds, and use of these compounds in the manufacture of medicaments for treating such diseases and medical conditions in a subject. Formula (IA) with the provisio that either R2or R3 is (Z).

PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS

The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES

The present invention relates to a class of melanocortin MCR4 agonists of general formula (I), wherein the variables and substituents are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, particularly in the treatment of sexual dysfunction and obesity, to intermediates useful in their synthesis and to compositions containing them.

Sulfonamides

The invention relates to compounds of the general formula in which R1, R2, R3, R4, R2′, R3′, R4′, R5, and X is —CHR— are as defined in the specification. The invention also provides pharmac

Preparation and antioxidant activity of α-pyridoin and its derivatives

Focusing on α-pyridoin (1, 1,2-di(2-pyridyl)-1,2-ethenediol) as the lead compound of the novel antioxidative enediol, we synthesized 5,5′- or 6,6′-bis-substituted derivatives of 1 from disubstituted pyridines. The antioxidant activity of 1 and its synthetic derivatives 2-7 was evaluated by DPPH (1,1-diphenyl-2-picrylhydrazyl radical) scavenging assay and inhibition of lipid peroxidation. In the DPPH assay, 1 exhibited an activity stronger than that of ascorbic acid, and 5,5′-dimethyl-(5) or 5,5′-dimethoxy- substituted derivatives (6) exhibited more potent activity than 1. The DPPH scavenging activities of α-pyridoins were correlated with their oxidation potential and thus the electron density of enediol. 5 and 6 effectively inhibited lipid peroxidation in the rat liver microsome/tert-butyl hydroperoxide system. Therefore, 5 and 6 serve as good candidates for a pharmacologically useful enediol antioxidant.

Non-peptide bombesin receptor antagonists

The compounds of the instant invention are novel compounds of Formula I or a pharmaceutically acceptable salt thereof wherein Ar is phenyl or pyridyl unsubstituted or substituted. Ar1can be independently selected from Ar and can also include pyridyl-N-oxide, indolyl, imidazole, and pyridyl; R3can be independently selected from Ar or is hydrogen, hydroxy, NMe2, N-methyl-pyrrole, imidazole, tetrazole, thiazole (a), (b), (c), or (d), wherein Ar2is phenyl or pyridyl. The instant compounds antagonize the bombesin receptors in mammals and are therefore effective in treating and/or preventing depression, psychoses, seasonal affective disorders, cancer, feeding disorders, gastrointestinal disorders, inflammatory bowel disease, sleep disorders, and memory impairment.

Synthesis of (R)-(+)-methyl 3-amino-3-(5-hydroxy-2-pyridinyl)propanoate, an analog of L-azatyrosine

A concise asymmetric synthesis of (R)-(+)-methyl 3-amino-3-(5-hydroxy-2-pyridinyl)propanoate 2, a β-amino acid analog of L-azatyrosine 1 starting from the commercially available (-)-Andersen reagent (-)-3 in good overall yield is described.

2--1H-thienoimidazoles. A Novel Class of Gastric H+/K+-ATPase Inhibitors

2-thienoimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase.The isomers of the two possible thienoimidazole series were found to be potent inhibitors of gastric acid secretion in vitro and in vivo.Structure-activity relationships indicate that especially lipophilic alkoxy, benzyloxy, and phenoxy substituents with additional electron-demanding properties in the 4-position of the pyridine moiety combined with an unsubstituted thienoimidazole lead to highly active compounds with a favorable chemical stability.Various substitution patterns in the thienoimidazole moiety result in lower biological activity.The heptafluorobutyloxy derivative saviprazole (HOE 731, 5d) was selected for further development and is currently undergoing clinical evaluation.Comprehensive pharmacological studies indicate a pharmacodynamic profile different to omeprazole, the first H+/K+-ATPase blocker introduced on the market.